PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 7, 2014--
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it is
offering $100 million of its common stock in a proposed underwritten
public offering. In addition, Pacira intends to grant the underwriters a
30-day option to purchase up to $15 million of additional shares of
common stock. The offering is subject to market conditions and there can
be no assurance as to whether or when the offering may be completed.
Jefferies LLC, Barclays Capital Inc. and BofA Merrill Lynch are acting
as the joint book-running managers and underwriters for the proposed
offering.
A shelf registration statement relating to the shares was filed with the
SEC and is effective. A preliminary prospectus supplement related to the
offering has been filed with the SEC and is available on the SEC’s
website located at http://www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying
prospectus relating to this offering may be obtained from Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue,
12th Floor, New York, NY, 10022, by telephone at 877-547-6340 or by
email at Prospectus_Department@Jefferies.com,
from Barclays Capital Inc., c/o Broadridge Financial Solutions, at 1155
Long Island Avenue, Edgewood, NY 11717, or by calling 1-888-603-5847 or
by emailing Barclaysprospectus@broadridge.com
or from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn:
Prospectus Department, or via e-mail at dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities. There shall not be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is a specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company’s current emphasis is the
development of non-opioid products for postsurgical pain control, and
its lead product, EXPAREL® (bupivacaine liposome injectable suspension),
was commercially launched in the United States in April 2012. EXPAREL
and two other products have utilized the Pacira proprietary product
delivery technology DepoFoam®, a unique platform that encapsulates drugs
without altering their molecular structure and then releases them over a
desired period of time.
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to our expectations
regarding the completion of the proposed public offering. Actual results
or developments may differ materially from those projected or implied in
these forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties related
to whether or not we will be able to raise capital through the sale of
shares of common stock, the final terms of the proposed offering, market
and other conditions, the satisfaction of customary closing conditions
related to the proposed public offering and the impact of general
economic, industry or political conditions in the United States or
internationally. There can be no assurance that we will be able to
complete the proposed public offering on the anticipated terms, or at
all. Additional risks and uncertainties relating to the proposed
offering, Pacira and our business are discussed in the “Risk Factors”
section of our most recent Annual Report on Form 10-K for the fiscal
year ended December 31, 2013, in other filings that we periodically make
with the SEC and in the preliminary prospectus supplement related to the
proposed offering filed with the SEC on or about the date hereof. In
addition, the forward-looking statements included in this press release
represent our views as of the date of this press release. We anticipate
that subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking statements
at some point in the future, we specifically disclaim any obligation to
do so. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this
press release.
Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
Jessica Cho, 973-254-3574
